CRISPR and Cas Gene Market Key Players and Forecast by 2030

[Research Report] CRISPR and Cas gene market size is projected to grow from US$ 2.78 billion in 2022 to US$ 15.10 billion by 2030; the market is estimated to record a CAGR of 23.6% during 2022–2030.

Market Insights and Analyst View:

The report includes growth prospects owing to the current CRISPR and Cas gene market trends and their foreseeable impact during the forecast period. Factors such as the increasing prevalence of cancer and genetic diseases, and the growing adoption of CRISPR-based screens with improved genomic targets propel the market growth. However, off-target effects and ethical concerns associated with CRISPR technology impede the growth of the market. In the coming years, increasing research funding for genomic studies and efforts made to demonstrate the effectiveness of CRISPR in genomics are likely to bring new trends into the market.

The CRISPR technology is useful in identifying mutations in many tumors. They recognize modified proteins that are specific to human tumors. Therefore, personalized treatments enabled by CRISPR technology for chronic diseases such as cancer drive the market expansion. In addition, factors such as investments by biotech companies in new treatments; increased genomic research and development; and the rising burden of cancer, bloodborne diseases, and so on are facilitating the CRISPR and Cas gene market growth. However, the use of CRISPR in drug development and therapeutic procedures is limited by its possibility of going off target, which limits the market progress.

Growth Drivers:

Increasing Prevalence of Cancer and Genetic Disorders Drives Market Growth

According to the American Cancer Society, the estimated number of people diagnosed with cancer in the US was 1.9 million in 2022. Additionally, a paper published in November 2022 in the Nature Journal states that researchers can use CRISPR gene editing to alter immune cells to recognize altered proteins specific to a person's tumors. These cells can then be safely delivered into the body to locate their targets for elimination, thus aiding in a personalized treatment option against cancer and other chronic diseases.

The increasing prevalence of genetic disorders further drives the need for gene editing technologies such as CRISPR and Cas genes. According to the World Health Organization (WHO), millions of people worldwide are affected by genetic disorders, as almost 1 in 20 live births has a genetic disorder. The CRISPR/Cas system can be used as a potential tool in developing treatment approaches for various genetic diseases, including sickle cell anemia, cystic fibrosis, and Huntington's disease. Many clinical trials are ongoing for testing the safety and effectiveness of CRISPR-based therapies in genetic disorders. Thus, the increasing demand for CRISPR and Cas gene technologies in various therapeutic areas to treat cancer and other chronic and genetic diseases fuels the CRISPR and Cas gene market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

CRISPR and Cas Gene Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The CRISPR and Cas gene market analysis has been carried out by considering the following segments: product & service, application, and end user.

Segmental Analysis:

By application, the CRISPR and Cas gene market is bifurcated into biomedical and agriculture. The biomedical segment held a larger market share in 2022. The same segment is anticipated to register a higher CAGR of 23.8% during the forecast period. CRISPR gene editing technologies are being used in different areas of life sciences. Well-established delivery methods and nanocarrier usage have further improved the effectiveness and specificity of this technology. Various studies have been conducted to explain the use of this method to modify human somatic cell and pluripotent stem cell genomes. Some companies also offer commercial kits and services to assist researchers through the use of CRISPR gene editing techniques.

Improving agricultural production through innovative breeding technologies has resulted in better access to nutrient-dense foods worldwide. In June 2019, researchers at Cold Spring Harbor Laboratory implemented CRISPR/Cas9 technology for inducing mutations in the flowering suppressor of tomatoes, resulting in rapid flowering and improved compact growth of tomatoes, ultimately, leading to early yield.

The CRISPR and Cas gene market, by product & service, is divided into products and services. The products segment held a larger market share in 2022. The same segment is expected to register a higher CAGR of 23.9% during the forecast period. Numerous cutting-edge technologies such as CRISPR and Cas gene editing kits have been developed and introduced to meet the growing demand. An upsurge in the share of these kits in the overall market is attributed to the availability of improved single products that can achieve different goals, including simple gene knockouts, reduced off-target cutting, selective genome cleavage, genome engineering, and higher specificity. Increased investments in research and development related to gene editing would further benefit the overall CRISPR and Cas Gene market during the forecast period.

The market, by end user, is categorized into biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations (CROs) and CDMOs. The biotechnology and pharmaceutical companies segment held the largest CRISPR and Cas gene market share in 2022. It is anticipated to register the highest CAGR of 24.2% during the forecast period. Biotechnology and pharmaceutical companies use these technologies to quickly identify and validate new therapeutic targets as well as to create better biological models of human diseases in less time. They also use gene modification techniques for commercial purposes.

Regional Analysis:

The scope of the CRISPR and Cas gene market report entails North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest CRISPR and Cas gene market share. The market growth in this region is driven by flourishing research and development operations in the biopharmaceuticals industry, as well as the involvement of several pharmaceutical companies in the development of novel therapeutics. In May 2020, Merck KGaA received approval from the US Food and Drug Administration (FDA) for two CRISPR Cas9-driven gene editing patents. In addition, various federal initiatives in the US and Canada support agricultural biotechnology research and the commercial release of CRISPR-based plant products. Many pharmaceutical and seed companies have invested in growth strategies such as partnerships, acquisitions, and collaborations to advance the pharmaceutical market and crop growth, respectively, which would further bolster the demand for CRISPR technology in these industries.

Europe is expected to occupy the second-largest share in the global CRISPR and Cas gene market. European authorities have introduced stricter regulations for new technologies, including gene therapy and genetically modified organisms. Despite strict regulations, the region is rapidly adopting CRISPR techniques in biomedical, medical, agricultural, and therapeutic applications.

Asia Pacific is expected to witness the fastest CAGR of 24.3% in the market during the forecast period. The market growth in this region is ascribed to increasing government investments in research and development to develop novel treatments. Companies and research institutes in China are conducting research on genome editing for drug development, and they have recently announced several clinical trials to seek approval for the use of CRISPR in cancer treatment. In March 2021, Setsuro Tech, a Japanese biotech company, received a patent for CRISPR-Cas9 technology developed by Dublin-based ERS Genomics. Such initiatives are expected to propel the adoption of CRISPR technology in Asia Pacific in the future.

CRISPR and Cas Gene Market Regional Insights

The regional trends and factors influencing the CRISPR and Cas Gene Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses CRISPR and Cas Gene Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

CRISPR and Cas Gene Market Report Scope

CRISPR and Cas Gene Market Players Density: Understanding Its Impact on Business Dynamics

The CRISPR and Cas Gene Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the CRISPR and Cas Gene Market are:

1. CRISPR Therapeutics
2. BRAIN Biotech AG
3. Thermo Fisher Scientific
4. Merck KGaA
5. Editas Medicine

Disclaimer: The companies listed above are not ranked in any particular order.

Industry Developments and Future Opportunities:

The CRISPR and Cas gene market forecast can help stakeholders in this marketplace plan their growth strategies. A few of the strategic developments by leading market players are listed below:

• In February 2023, Ensoma acquired Twelve Bio ApS to further develop its in vivo engineered cell medicines portfolio. Twelve Bio is a company engaged in exploring therapeutic applications of next-generation CRISPR-Cas drugs.
• In December 2022, a researcher from the University of California started off with a clinical trial entitled “Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease” to evaluate hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9-edited red blood cells—known as CRISPR_SCD001 Drug Product).
• In November 2022, researchers at the Massachusetts Institute of Technology developed a CRISPR-based PASTE tool that inserts large DNA sequences into desired cell locations. The technique can be potentially used in the treatment of various genetic diseases.
• In November 2021, Health Canada approved the clinical trial application submitted by CRISPR Therapeutics and ViaCyte for VCTX210, a CRISPR-engineered stem cell therapy for treating type 1 diabetes.

Competitive Landscape and Key Companies:

CRISPR Therapeutics; Thermo Fisher Scientific; Merck; GenScript; Qiagen; Takara Bio Inc.; Brain Biotech AG; Intellia Therapeutics, Inc.; New England Biolabs; and Editas Medicine, Inc. are among the prominent companies profiled in the CRISPR and Cas gene market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.